Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 63Colorectal Neoplasms 30Biliary Tract Neoplasms 29Cholangiocarcinoma 27Pancreatic Neoplasms 26Liver Neoplasms 18Stomach Neoplasms 13Esophageal Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 8Ovarian Neoplasms 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Carcinoma 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Prostatic Neoplasms 5Colonic Neoplasms 5Uterine Cervical Neoplasms 4Lung Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Adenocarcinoma 4Neoplasms 3

Interventions

Oxaliplatin 11Mitomycin 11Leucovorin 7Hyperthermic Intraperitoneal Chemotherapy 7Irinotecan 6Fluorouracil 6Cisplatin 4Capecitabine 4Surveys and Questionnaires 3Doxorubicin 3Cytoreduction Surgical Procedures 3dehydroftorafur 2Trastuzumab 2Thalidomide 2Mitozytrex 2Melphalan 2Interleukin-12 Subunit p35 2Floxuridine 2Drug Therapy 2Cetuximab 2Biopsy 2tipifarnib 1surufatinib 1sodium thiosulfate 1sintilimab 1nintedanib 1nilotinib 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Appendiceal Neoplasms × durvalumab × Gastrointestinal × Clear all
NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Ludwig Institute for Cancer Research

Phase 1/2 Completed
67 enrolled 16 charts
GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡